



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Efineptakin alfa

Cat. No.:	HY-P99908
CAS No.:	2026634-47-7
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 <sup>+</sup> and CD8 <sup>+</sup> cells in both human and mice. Efineptakin alfa can be used for glioblastoma research <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IL7R								
<b>In Vivo</b>	<p>Efineptakin alfa (10 mg/kg, IM, single) combined with SLC-3010 (1.8 mg/kg, IV, single) inhibits tumor growth in MC38-bearing mice<sup>[1]</sup>.</p> <p>Efineptakin alfa (10 mg/kg) mitigates RT-related lymphopenia, increases cytotoxic CD8 T lymphocytes systemically and in the tumor, and improves survival in orthotopic glioma-bearing mice<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion</td> </tr> <tr> <td>Result:</td> <td>Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFN<math>\gamma</math> production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.</td> </tr> </table>	Animal Model:	C57BL/6 mice bearing intracranial tumors (GL261 or CT2A) <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion	Result:	Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFN $\gamma$ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.
Animal Model:	C57BL/6 mice bearing intracranial tumors (GL261 or CT2A) <sup>[1]</sup>								
Dosage:	10 mg/kg								
Administration:	On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion								
Result:	Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFN $\gamma$ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.								

### REFERENCES

[1]. Campian JL, et al. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239.

[2]. Seungtae Baek, et al. rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex. 2022 AACR Abstract #4199.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA